We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug ...

When Pasadena-based Arrowhead Pharmaceuticals Inc. signed a huge licensing and collaboration deal with Cambridge, ...

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...

Arrowhead Pharmaceuticals said it earned a $100 million milestone payment from Sarepta Therapeutics. The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets ...

Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $30.41. The company has a market capitalization of $2.22 billion, a P/E ratio of -3.11 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said it has signed an asset purchase agreement between Sanofi and a subsidiary of the ...

Arrowhead Pharmaceuticals Stock Down 5.4 % Shares of NASDAQ:ARWR opened at $13.93 on Thursday. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $30.41.